Company name: Ancera, Inc.

Company size: 56 employees

Role in this company: Led the company through ~90M USD from Series A through growth stage under various deal structures•Engaged with board members and advisors to build and update 3 yr strategic plan, incl. exit options•Led International sales and market development - expanded in MENA and APAC for export controls•Led product development & commercialization of SaaS platform (Product, Software, Data Science, Hardware) for microbial security in food supply chain to create and capture value•Led operations (purchasing, fi

Company name: JSR Corporation

Company size: 2,000 employees

Role in this company: Developlong term manufacturing strategy for peptides, tetramers, and other MHC molecules to improve profitability, Reduced custom molecule manufacturing costs by 30%•Manage 3 sites (CA, MA, and IL) to ensure all sales activities are supported through R&D and Ops•Identified process and technology improvements to reduce custom product lead time from 7-9 wks to 2 wks•Established standardize cost structure and improve employee retention at Des Plaines, IL, Woburn, MA•Set the direction for ISO 13485

Company name: BTG PLC

Company size: 5,000 employees

Role in this company: Directed mfg and service operations for vascular business unit (durables & consumables)•Implemented “best-in-class” manufacturing methodologies through optimization of production processes, integrated systems, material flow, and facilities to improve quality, increase throughput and reduce cost•Built lean manufacturing expertise and DFM capability to facilitate transfer of development projects to manufacturing from in-house R&D projects or acquisition•Oversaw and monitored progress of operations

Company name: Medtronic

Company size: 50,000 employees

Role in this company: •Managed strategic planning process for MIT group ($10B revenue) and prioritize resource allocationactivities through portfolio moves in high growth sub markets; Awarded Star of Excellence by CEO •Owned deal prioritization activities in alignment with inorganic growth targets ($125M) for the MIT group •Evaluated operational health of Medtronic’s 34 operations worldwide for consolidation and streamlining toexecute on a 5-year strategy of value capture